MEI Pharma renames itself Lite Strategy, Inc.

MEI Pharma, Inc. has changed its corporate name to Lite Strategy, Inc., effective September 10, 2025, through an amendment to its certificate of incorporation filed in Delaware.

Rhea-AI Filing Summary

MEI Pharma, Inc. has changed its corporate name to Lite Strategy, Inc., effective September 10, 2025, through an amendment to its certificate of incorporation filed in Delaware. Under Delaware law, this name change did not require a stockholder vote and does not alter the rights of existing stockholders.

Beginning September 11, 2025, the company’s common stock, par value $0.00000002 per share, will stop trading on the Nasdaq Capital Market under the ticker symbol “MEIP” and will start trading under the new ticker symbol “LITS.” The company also issued a news release on September 10, 2025, to announce the new name and ticker.

8-K Event Classification

Item 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

1 item

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What corporate change did MEIP disclose in this 8-K filing?

The company disclosed that MEI Pharma, Inc. has changed its name to Lite Strategy, Inc., effective September 10, 2025, through an amendment to its amended and restated certificate of incorporation filed with the Delaware Secretary of State.

Will the MEIP stock ticker change as part of the name change?

Yes. The company’s common stock, par value $0.00000002 per share, which trades on the Nasdaq Capital Market, will cease trading under the ticker symbol “MEIP” and commence trading under the ticker symbol “LITS” on September 11, 2025.

Does the name change to Lite Strategy, Inc. affect stockholder rights?

No. The company states that the name change does not affect the rights of its stockholders. Only the corporate name and ticker symbol are changing as described.

Was a stockholder vote required for MEI Pharma’s name change to Lite Strategy, Inc.?

No. The company explains that, pursuant to the Delaware General Corporation Law, a stockholder vote was not necessary to effectuate the name change.

Did the company issue a press release about the new name and ticker?

Yes. On September 10, 2025, the company issued a news release announcing the name change and new ticker symbol. This press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the Exchange Act.

What exhibits are included with this MEIP (Lite Strategy, Inc.) 8-K filing?

The exhibits include the Certificate of Amendment as Exhibit 3.1, the press release dated September 10, 2025 as Exhibit 99.1, and the Cover Page Interactive Data File formatted as inline XBRL as Exhibit 104.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/10/2025 - 09:00 AM EDT Learn about SEC filing dates

false0001262104--06-3000012621042025-09-102025-09-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2025

MEI Pharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41827	51-0407811
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
9920 Pacific Heights Blvd., Suite 150
San Diego, California				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 369-7100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00000002 par value		MEIP		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Effective September 10, 2025, MEI Pharma, Inc. (the “Company”) changed its name to Lite Strategy, Inc. pursuant to an amendment to its amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware (the “Name Change”). Pursuant to the Delaware General Corporation Law, a stockholder vote was not necessary to effectuate the Name Change and it does not affect the rights of the Company’s stockholders.

On September 11, 2025, the Company’s common stock, par value $0.00000002 per share, which trades on the NASDAQ Capital Market, will cease trading under the ticker symbol “MEIP” and commence trading under the ticker symbol “LITS.”

The foregoing description of the amendment to the Company's amended and restated certificate of incorporation does not purport to be complete and is qualified in its entirety by reference to the full text of the certificate of amendment, which is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On September 10, 2025, the Company issued a news release announcing the Name Change and new ticker symbol. The news release is being furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in this item, including Exhibit 99.1, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Exhibit Title
3.1		Certificate of Amendment.
99.1		Press release, dated September 10, 2025.
104		Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			MEI PHARMA, INC.
Date:	September 10, 2025	By:	/s/ Justin J. File
			Justin J. File Acting Chief Executive Officer, Chief Financial Officer and Secretary